Amphastar Pharmaceuticals, Inc. Stockholders Equity

Quick Answer

Amphastar Pharmaceuticals, Inc. reported Stockholders Equity of $788.80 million for fiscal year 2025.

Amphastar Pharmaceuticals, Inc. Stockholders Equity — Annual History

Fiscal Year Stockholders Equity YoY Change
2025 $788.80M +7.7%
2024 $732.30M +14.5%
2023 $639.42M +21.0%
2022 $528.66M +18.7%
2021 $445.52M +10.7%
2020 $402.31M +5.5%
2019 $381.37M +14.7%
2018 $332.44M -0.4%
2017 $333.74M +1.4%
2016 $329.25M +11.4%
2015 $295.51M +4.8%
2014 $281.86M +12.1%
2013 $251.54M +7.8%
2012 $233.44M +12.0%
2011 $208.52M

Quarterly Stockholders Equity

Quarter Ending Stockholders Equity YoY QoQ
September 30, 2025 $776.75M +6.7% +2.5%
June 30, 2025 $757.48M +6.2% +0.8%
March 31, 2025 $751.28M +11.7% +2.6%
December 31, 2024 $732.30M +14.5% +0.6%
September 30, 2024 $727.68M +22.3% +2.0%
June 30, 2024 $713.35M +21.1% +6.1%
March 31, 2024 $672.36M +22.6% +5.2%
December 31, 2023 $639.42M +21.0% +7.4%
  • Amphastar Pharmaceuticals, Inc. showed an increase of +7.7% in Stockholders Equity compared to the prior fiscal year.
  • Over the 2011–2025 period, Amphastar Pharmaceuticals, Inc.’s stockholders equity has grown by 278.3% (from $208.52 million to $788.80 million).
  • The most recent figure is from Amphastar Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment